- Poster presentation
- Open Access
Egr-1 mediates the suppressive effect of IL-1 on PPARγ expression in human OA chondrocytes
© Nebbaki et al; licensee BioMed Central Ltd. 2012
- Published: 28 November 2012
- Articular Cartilage
- Suppressive Effect
- Activate Transcription Factor
- Nuclear Hormone Receptor
- Arthritic Disease
Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand activated transcription factor and member the nuclear hormone receptor superfamily. Several lines of evidence indicate that PPARγ have protective effects in osteoarthritis (OA). Indeed, PPARγ has been shown to down-regulate several inflammatory and catabolic responses in articular cartilage and chondrocytes and to be protective in animal models of OA.
We have previously shown that IL-1 down-regulated PPARγ expression in OA chondrocytes. In the present study we will investigate the mechanisms underlying this effect of IL-1.
Chondrocytes were stimulated with IL-1, and the level of PPARγ and Egr-1 protein and mRNA were evaluated using Western blotting and real-time reverse-transcription polymerase chain reaction, respectively. The PPARγ promoter activity was analyzed in transient transfection experiments. Egr-1 recruitment to the PPARγ promoter was evaluated using chromatin immunoprecipitation (ChIP) assays. Small interfering RNA (siRNA) approaches were used to silence Egr-1 expression.
We demonstrated that the suppressive effect of IL-1 on PPARγ expression requires de novo protein synthesis and was concomitant with the induction of the transcription factor Egr-1. ChIP analyses revealed that IL-1 induced Egr-1 recruitment at the PPARγ promoter. IL-1 inhibited the activity of PPARγ promoter and overexpression of Egr-1 potentiated the inhibitory effect of IL-1, suggesting that Egr-1 may mediate the suppressive effect of IL-1. Finally, Egr-1 silencing with small interfering RNA blocked IL-1-mediated down-regulation of PPARγ expression.
These results indicate that Egr-1 contributes to IL-1-mediated down-regulation of PPARγ expression in OA chondrocytes and suggest that this pathway could be a potential target for pharmacologic intervention in the treatment of OA and possibly other arthritic diseases.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.